amivantamab
janssen,genmab
['sclc', 'nsclc', 'chrysalis,(-chrysalis2),(-chrysalis-2),(-chrysalis 2)']
#asco22 dr. presents update on chrysalis from amivantamab in #met exon 14 skip mutation nsclc. while amivantamab is approved for #egfrex20, this bispecific targets both egfr and met with an even higher affinity for met (40 pm) than egfr (1.4 nm). 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him